STOCK TITAN

Regeneron Pharmaceuticals - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Overview

Regeneron Pharmaceuticals (NASDAQ: REGN) is a renowned American biotechnology company dedicated to inventing, developing, and commercializing transformative medicines for serious diseases. With its headquarters in Westchester County, New York, and a history dating back to 1988, Regeneron has established itself as a trusted innovator in the biopharmaceutical industry by consistently translating cutting‐edge science into life‐changing therapies.

Core Business and Technological Excellence

At the heart of Regeneron’s operations lies a deep commitment to scientific rigor and technological innovation. The company leverages proprietary VelociSuite® technologies, which include the groundbreaking VelocImmune® platform, to generate fully human antibodies and next-generation bispecific antibodies. These advanced techniques enable Regeneron to identify novel targets and rapidly develop therapies across a wide spectrum of indications such as eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic conditions, hematologic disorders, and rare diseases.

Research, Development and Collaborative Approach

Regeneron’s robust R&D engine is fueled by decades of biology expertise and an integrated approach to drug discovery. The company’s research framework harnesses data-powered insights and genetic medicine platforms to drive its clinical research programs. This commitment is reflected in its diverse pipeline of product candidates and regulatory pathways that emphasize both innovation and patient safety. Through strategic partnerships and collaborations with other key industry players, Regeneron further strengthens its technological capacity while expanding its reach in translational medicine.

Market Position and Significance in the Biotechnology Sector

In the competitive landscape of biotech and pharmaceuticals, Regeneron distinguishes itself through its consistent ability to translate scientific discoveries into marketed products. Its portfolio comprises therapies addressing complex diseases by utilizing targeted approaches involving monoclonal antibodies and complementary biologic modalities. The company’s methodical process—from early identification of druggable targets to rigorous clinical testing and eventual commercialization—underscores its expertise, high scientific standards, and commitment to improving patient outcomes.

Operational Strategy and Business Model

Regeneron generates revenue primarily through its commercialization of innovative therapies and strategic collaborations, which amplify its research capabilities. By focusing on conditions with significant unmet medical need, Regeneron positions itself as a dynamic entity capable of addressing diverse therapeutic challenges. Its strategies incorporate efficient drug development processes, collaborative research initiatives, and maintaining robust clinical trial portfolios—all without relying on time-sensitive information or financial forecasts.

E-E-A-T Focus and Investor Considerations

The company’s work is grounded in long-standing scientific expertise and a commitment to ongoing research. By adhering to stringent safety and efficacy protocols and maintaining transparent regulatory communications, Regeneron exemplifies the principles of Expertise, Experience, Authoritativeness, and Trustworthiness (E-E-A-T). For investors and analysts, Regeneron’s approach to innovation, its state-of-the-art proprietary technologies, and its history of successfully translating advanced science into viable therapies present a well-articulated model of modern biotechnology excellence.

Conclusion

Overall, Regeneron Pharmaceuticals represents a compelling example of how rigorous research, technological innovation, and strategic partnerships converge to create transformative medicines. Its consistent emphasis on high-quality science and unbiased, evidence-based development processes not only boosts its market presence but also reinforces its reputation as a trusted biopharmaceutical partner in the global healthcare arena.

  • Decades of scientific expertise
  • Innovative proprietary platforms
  • Diverse therapeutic pipeline
  • Robust R&D and clinical programs
  • Strategic collaborations and transparency
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced positive results from a pivotal Phase 3 trial of Dupixent (dupilumab) for treating eosinophilic esophagitis (EoE) in patients aged 12 and older. The trial demonstrated significant improvements in patients' ability to swallow, structural abnormalities in the esophagus, and reduced eosinophil counts. Presented at virtual ACG 2020 and UEG Week 2020, the data showed that 64% of patients treated with Dupixent achieved eosinophil levels below the diagnostic threshold. The FDA granted Breakthrough Therapy designation for Dupixent in EoE in September 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent (dupilumab), extending its approval in the EU for children aged 6 to 11 years with severe atopic dermatitis suitable for systemic therapy. Dupixent, a biologic, is already approved for older patients in the EU and U.S. Efficacy data from Phase 3 trials showed significant improvement in disease measures when combined with topical corticosteroids. A final decision by the European Commission is forthcoming.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced FDA approval for Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) as the first treatment for Zaire ebolavirus infection in patients of all ages. Inmazeb demonstrated superiority in reducing mortality compared to ZMapp and remdesivir in a clinical trial involving 681 patients. The approval was facilitated by a collaboration with BARDA, ensuring a steady supply for public health emergencies. Regeneron remains committed to making Inmazeb accessible and continues support for Ebola response efforts in affected regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) successfully met its primary and key secondary endpoints in a Phase 3 trial for children aged 6-11 with uncontrolled moderate-to-severe asthma. The study showed Dupixent reduced severe asthma attacks by up to 65% and improved lung function significantly within two weeks. Regulatory submissions in the U.S. and EU for this age group are anticipated by Q1 2021. The safety profile was consistent with previous findings, showing Dupixent as a promising option for children suffering from this serious condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
-
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will report its third quarter 2020 financial results on November 5, 2020, before the U.S. markets open. A conference call and webcast will be held at 8:30 AM ET on the same day. To participate, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International) with conference ID 1535889. Regeneron is known for developing life-transforming medicines and has seven FDA-approved treatments. Its innovative technologies, like VelociSuite, enhance drug development processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
Rhea-AI Summary

On September 29, 2020, Regeneron Pharmaceuticals announced promising results from a Phase 1/2/3 trial of REGN-COV2, its investigational antibody cocktail for COVID-19. The study showed significant reductions in viral load and symptom duration among non-hospitalized patients, particularly those without effective immune responses. Results indicated faster symptom alleviation and a favorable safety profile; both high and low doses of REGN-COV2 were well-tolerated. Regeneron plans to discuss these findings with regulatory agencies and host a webcast for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
covid-19
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi presented positive data from a pivotal trial of Libtayo (cemiplimab) for first-line treatment of advanced non-small cell lung cancer (NSCLC) at the ESMO Virtual Congress 2020. Libtayo demonstrated a 32% reduction in risk of death compared to chemotherapy, with a median overall survival of 22 months versus 14 months for chemotherapy. In patients with PD-L1 expression ≥50%, Libtayo showed a 43% reduction in death risk. The drug is being developed under a global collaboration agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced promising results from the Phase 2 trial of Libtayo® (cemiplimab) for advanced basal cell carcinoma (BCC) after hedgehog inhibitor therapy. The trial, presented at the ESMO Virtual Congress 2020, reported a 31% objective response rate (ORR) with 85% of responses ongoing at one year. Key findings include a median follow-up of 15 months, with a probability of overall survival at 92%. No new safety signals were observed, though 17% of patients discontinued treatment due to adverse events. Libtayo is still under investigation for this indication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals and the University of Oxford announced the RECOVERY trial to evaluate the investigational COVID-19 treatment REGN-COV2. This Phase 3 trial will compare the addition of REGN-COV2 to the standard care in COVID-19 hospitalized patients, assessing its impact on mortality and hospital stays. The trial aims to include at least 4,000 participants across 176 UK hospitals. The success of REGN-COV2 could provide significant insights into effective treatment options for COVID-19, complementing existing therapies like dexamethasone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
clinical trial covid-19

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $617 as of April 1, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 67.6B.

What is the core focus of Regeneron Pharmaceuticals?

Regeneron is a biotechnology company that specializes in discovering, developing, and commercializing innovative medicines for serious diseases using advanced scientific and technological approaches.

Which technologies underpin Regeneron’s research efforts?

The company utilizes its proprietary VelociSuite® and VelocImmune® platforms, which are central to its ability to generate fully human antibodies and next-generation bispecific antibodies.

In which therapeutic areas does Regeneron operate?

Regeneron develops therapies across several areas including eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic and hematologic conditions, as well as rare diseases.

How does Regeneron generate its revenue?

Revenue is primarily generated through the commercialization of approved therapies and strategic collaborations that enhance its research and development capabilities.

What differentiates Regeneron in the competitive biotech landscape?

Its commitment to cutting-edge technology, robust R&D pipeline, and a collaborative approach enable Regeneron to consistently transform scientific discoveries into marketable and efficacious treatments.

How long has Regeneron been active in the biotechnology field?

Regeneron was founded in 1988 and has since built a reputable track record for translating innovative science into transformative therapies.

What are the key elements of Regeneron’s business model?

The model emphasizes rigorous research and development, leveraging proprietary technologies, strategic partnerships, and a focus on addressing unmet medical needs while maintaining high standards of safety and efficacy.

How does Regeneron maintain its E-E-A-T (Expertise, Experience, Authoritativeness, Trustworthiness) standards?

By consistently investing in advanced research, adhering to strict clinical protocols, engaging transparently with regulatory authorities, and fostering innovations through collaborations, Regeneron demonstrates deep expertise and builds trust in the medical and investment communities.
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

67.56B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN